Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform
- PMID: 34065918
- PMCID: PMC8151139
- DOI: 10.3390/ijerph18105113
Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform
Abstract
Huntington's disease (HD) is a neurodegenerative dementia with a well recognised genetic cause. Alcohol misuse is a major environmental factor relevant to numerous neurological presentations, including HD. We explored the effects of alcohol intake on clinical features of HD by means of data from the Enroll-HD, which is a global registry study. A retrospective observational study making use of the Enroll-HD periodic dataset up to 2020 (in accordance with the Enroll-HD guidelines, encompassing 16,120 subjects with the HD gene (CAG expansion > 36), was carried out. This included 180 sites in 21 countries. The study looked at the association of alcohol use with the clinical presentation of HD, specifically looking into the age of first symptoms and HD severity. We also describe a specific case with manifest HD, a participant in the Enroll-HD study, whereby the patient's obsessionality was central to her pattern of high alcohol intake and to her successful avoidance of alcohol thereafter. A record of past problems with high alcohol intake was more common in the group with manifest HD (9.0%, n = 1121) when compared with the pre-manifest carriers of the HD genetic abnormality (2.3%, n = 339). Age at onset of symptoms was not significantly influenced by current alcohol misuse, or past misuse. The severity of clinical impairments in HD was influenced by alcohol. Patients who reported high alcohol intake in the past had a statistically significant increase in motor impairments, by the Unified Huntington's Disease Rating Scale total motor score (Kruskal-Wallis, post hoc Dunn's, p < 0.001), and a significantly higher burden of psychiatric symptoms by the Problem Behaviours Assessment score (Kruskal-Wallis, post hoc Dunn's, p < 0.01) compared with those not reporting high alcohol use. However, the past alcohol group did not have a lower Mini Mental State Examination score (Kruskal-Wallis, post hoc Dunn's, p > 0.05) The first symptom of HD, as determined by the assessing clinician, was more likely to be psychiatric disturbance in patients currently misusing alcohol or those with prior history of alcohol misuse (55% and 31% respectively) when compared with controls (5%). Individual case experience, such as that presented in this study, shows that HD and alcohol, two major genetic and environmental contributors to neurodegeneration, interact in producing clinical problems. However, the complexities of these interactions are difficult to define, and may require larger studies dedicated to exploring the various factors in this interaction.
Keywords: Huntington’s disease; alcohol; neurodegeneration.
Conflict of interest statement
The authors do not have any conflicts of interest.
Figures


Similar articles
-
Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.Lancet Neurol. 2018 Nov;17(11):986-993. doi: 10.1016/S1474-4422(18)30294-1. Epub 2018 Sep 19. Lancet Neurol. 2018. PMID: 30243861
-
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124
-
Age of onset and behavioral manifestations in Huntington's disease: An Enroll-HD cohort analysis.Clin Genet. 2021 Jan;99(1):133-142. doi: 10.1111/cge.13857. Epub 2020 Oct 16. Clin Genet. 2021. PMID: 33020896
-
Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD.J Neurol. 2018 Nov;265(11):2548-2561. doi: 10.1007/s00415-018-9013-6. Epub 2018 Aug 27. J Neurol. 2018. PMID: 30167880 Review.
-
What do we know about Late Onset Huntington's Disease?J Huntingtons Dis. 2017;6(2):95-103. doi: 10.3233/JHD-170247. J Huntingtons Dis. 2017. PMID: 28671137 Free PMC article. Review.
Cited by
-
Modifiable factors associated with Huntington's disease progression in presymptomatic participants.Ann Clin Transl Neurol. 2024 Jul;11(7):1930-1941. doi: 10.1002/acn3.52120. Epub 2024 Jun 10. Ann Clin Transl Neurol. 2024. PMID: 38855890 Free PMC article.
-
Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease.Sleep Sci. 2024 Feb 15;17(2):e199-e202. doi: 10.1055/s-0043-1777783. eCollection 2024 Jun. Sleep Sci. 2024. PMID: 38846594 Free PMC article.
References
-
- Novak M.J., Tabrizi S.J. Huntington’s disease: Clinical presentation and treatment. Int. Rev. Neurobiol. 2011;98:297–323. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous